Overview

MEtoclopramide, DExamethasone or Axoli to Prevent or Delay Chemotherapy-induced Nausea and Vomiting in Moderately Emetogenic Non-AC-based Chemotherapy

Status:
Completed

Trial end date:
2019-03-01

Target enrollment:

Participant gender:

Summary

In this phase III non-inferiority trial, the aim is to evaluate whether metoclopramide and palonosetron prophylactic antemetic treatment are non-inferior to dexamethasone with regard to its efficacy to prevent delayed chemotherapy-induced nausea and vomiting (CINV) induced by non- anthracyclines plus cyclophosphamide (AC) based moderately emetogenic chemotherapy (MEC).

Phase:

Phase 3

Details

Lead Sponsor:

VU University Medical Center

Collaborators:

Gemini Ziekenhuis
Medisch Centrum Alkmaar
Noordwest Ziekenhuisgroep
Rijnstate
Tergooiziekenhuizen locatie Hilversum
Waterland Ziekenhuis
Zaans Medisch Centrum
Ziekenhuis Amstelland

Treatments:

BB 1101
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate
Emetics
Metoclopramide
Palonosetron